This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

• Exane BNP Paribas analyst Kevin Grundy initiated coverage on Constellation Brands, Inc. STZ with a Neutral rating and announced a price target of $261. Constellation Brands shares closed at $239.66 on Friday. See how other analysts view this stock.
• TD Cowen analyst Joseph Thome initiated coverage on Viridian Therapeutics, Inc. VRDN with a Buy rating. Viridian Therapeutics shares closed at $20.20 on Friday. See how other analysts view this stock.
• Canaccord Genuity analyst Edward Nash initiated coverage on Apogee Therapeutics, Inc. APGE with a Buy rating and announced a price target of $89. Apogee Therapeutics shares closed at $43.46 on Friday. See how other analysts view this stock.
• UBS analyst Timothy Arcuri initiated coverage on Arm Holdings plc ARM with a Buy rating and announced a price target of $160. ARM shares closed at $135.99 on Friday. See how other analysts view this stock.
• HC Wainwright & Co. analyst Mitchell Kapoor initiated coverage on Sarepta Therapeutics, Inc. SRPT with a Sell rating and announced a price target of $80. Sarepta Therapeutics shares closed at $114.23 on Friday. See how other analysts view this stock.

Considering buying SRPT stock? Here’s what analysts think:

Read This Next:

• Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin